Lundbeck broadens phase III trial of Vyepti in children
Previous participants in Lundbeck trials are being brought together in a new phase III study that aims to investigate the long-term safety of use of migraine drug Vyepti in childhood.
by mikkel aabenhus hemmingsen, translated by catherine brett
Children and young people who have previously participated in clinical trials of migraine drug Vyepti have now been offered the chance to remain in treatment for a longer period.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Lundbeck Head of R&D denies allergy aspirations
For subscribers
